JPH0144719B2 - - Google Patents
Info
- Publication number
- JPH0144719B2 JPH0144719B2 JP55057424A JP5742480A JPH0144719B2 JP H0144719 B2 JPH0144719 B2 JP H0144719B2 JP 55057424 A JP55057424 A JP 55057424A JP 5742480 A JP5742480 A JP 5742480A JP H0144719 B2 JPH0144719 B2 JP H0144719B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- reaction
- extract
- organic solvent
- miscible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 79
- 239000000284 extract Substances 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 55
- 239000003960 organic solvent Substances 0.000 claims description 26
- 241000893536 Epimedium Species 0.000 claims description 24
- 235000018905 epimedium Nutrition 0.000 claims description 23
- 239000002244 precipitate Substances 0.000 claims description 22
- 238000000862 absorption spectrum Methods 0.000 claims description 19
- 239000006286 aqueous extract Substances 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 14
- 150000001298 alcohols Chemical class 0.000 claims description 12
- 150000002576 ketones Chemical class 0.000 claims description 11
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 claims description 10
- 150000002170 ethers Chemical class 0.000 claims description 9
- -1 fatty acid esters Chemical class 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 claims description 5
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 5
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 5
- 229940074386 skatole Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000000605 extraction Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 238000001914 filtration Methods 0.000 description 17
- 239000012980 RPMI-1640 medium Substances 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 230000000242 pagocytic effect Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010057249 Phagocytosis Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000008782 phagocytosis Effects 0.000 description 9
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 8
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000005238 degreasing Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000006268 Sarcoma 180 Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000001617 migratory effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000003399 chemotactic effect Effects 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OYDXRQHMSA-N 1-[(2r,4s,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H]([14CH2]O)[C@@H](O)C1 IQFYYKKMVGJFEH-OYDXRQHMSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000893531 Epimedium koreanum Species 0.000 description 1
- 241001362411 Epimedium sagittatum Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- POIRVLZGTSWEMG-UHFFFAOYSA-N Magnoflorin Natural products N1CCC2=CC(OC)=C(O)C3=C2C1CC1=CC=C(OC)C(O)=C13 POIRVLZGTSWEMG-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OGYXOOJUJQIDOX-UHFFFAOYSA-N epimedoside A Natural products OC1C(O)C(O)C(C)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=C(CC=C(C)C)C(OC3C(C(O)C(O)C(CO)O3)O)=CC(O)=C2C1=O OGYXOOJUJQIDOX-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000002557 fixed macrophage Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5742480A JPS56156219A (en) | 1980-04-30 | 1980-04-30 | Extract from plant of genus epimedium, its preparation and immunological enhancer containing the same as active constituent |
| DE3116695A DE3116695C2 (de) | 1980-04-30 | 1981-04-28 | Neuer Pflanzenextrakt, Verfahren zu seiner Herstellung und ein ihn enthaltendes Arzneimittel |
| NL8102073A NL8102073A (nl) | 1980-04-30 | 1981-04-28 | Nieuw extract uit een plant van het geslacht epimedium sp., werkwijze voor het bereiden van het extract, de immuniteit stimulerend middel, dat het extract als effectieve component omvat en immunotherapie onder toepassing van het extract. |
| CA000376500A CA1153696A (en) | 1980-04-30 | 1981-04-29 | Extract from plant of genus epimedium sp., process for preparation of said extract, immunostimulating agent comprising said extract as effective component and immunotherapy by using said extract |
| GB8113312A GB2076002B (en) | 1980-04-30 | 1981-04-30 | Extract and process for extraction from plant of genus epimedium sp immunostimulating agent comprising said extract and extract for use in immunotherapy |
| FR8108748A FR2481704A1 (fr) | 1980-04-30 | 1981-04-30 | Extrait de plantes du genre epimadium sp procede pour la preparation de cet extrait, agent immunostimulant comprenant cet extrait comme composant actif et immunotherapie obtenue en utilisant cet extrait |
| BE2/59137A BE888635A (fr) | 1980-04-30 | 1981-04-30 | Nouvel extrait de plante, procede de preparation, agent immunostimulant comprenant cet extrait comme composant efficace et immunotherapie par son utilisation, |
| CH2842/81A CH652028A5 (de) | 1980-04-30 | 1981-04-30 | Extrakt aus pflanzen vom genus epimedium sp., verfahren zur herstellung dieses extrakts und verwendung des extrakts als wirksame komponente in einem immunstimulierenden mittel. |
| IT21484/81A IT1136593B (it) | 1980-04-30 | 1981-04-30 | Estratto da piante del genere epimedium,procedimento per la preparazione di detto estratto,agente immunostimolante che comprende detto estratto come componente efficace e immunoterapia mediante l'impiego di detto estratto |
| US06/520,760 US4501736A (en) | 1980-04-30 | 1983-08-08 | Extract from barrenwort |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5742480A JPS56156219A (en) | 1980-04-30 | 1980-04-30 | Extract from plant of genus epimedium, its preparation and immunological enhancer containing the same as active constituent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56156219A JPS56156219A (en) | 1981-12-02 |
| JPH0144719B2 true JPH0144719B2 (it) | 1989-09-29 |
Family
ID=13055266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5742480A Granted JPS56156219A (en) | 1980-04-30 | 1980-04-30 | Extract from plant of genus epimedium, its preparation and immunological enhancer containing the same as active constituent |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS56156219A (it) |
| BE (1) | BE888635A (it) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2918569B1 (fr) * | 2007-07-09 | 2012-09-28 | Engelhard Lyon | Substances inhibant la glycation des proteines. |
| WO2012058957A2 (zh) * | 2010-11-05 | 2012-05-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 淫羊藿多糖及其组分和它们用于疫苗佐剂的用途 |
-
1980
- 1980-04-30 JP JP5742480A patent/JPS56156219A/ja active Granted
-
1981
- 1981-04-30 BE BE2/59137A patent/BE888635A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56156219A (en) | 1981-12-02 |
| BE888635A (fr) | 1981-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4511559A (en) | Biologically active polysaccharide concentrates and process for production of preparates containing such substances | |
| US4843067A (en) | Polysaccharide containing pharmaceutical composition for increasing the immune function | |
| CN117500842A (zh) | Cs-4发酵菌丝体杂聚多糖及其制备方法与用途 | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| US4944946A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| WO1982003771A1 (fr) | Polysaccharide ps-a isole a partir de la plante appartenant au genre epidemium violaceum morr. et decne., procede de preparation, et agent de prevention de l'infection et stimulateur de l'immunite contenant le polysaccharide a titre d'ingredient efficace | |
| JPH0539305A (ja) | アストラガルス・メンブラナセウスから抽出した免疫 変調性多糖類及びこれらを含有する薬剤組成物 | |
| US4629627A (en) | Antiviral substance and the manufacturing method thereof | |
| JP2000154151A (ja) | 免疫抑制剤 | |
| JPH0144719B2 (it) | ||
| US4501736A (en) | Extract from barrenwort | |
| Nakatani et al. | N-Cyclohexyl linoleamide: Metabolism and cholesterol-lowering effect in rats | |
| US4985247A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| EP0014471B1 (en) | Acylated derivatives of a water extract of anemarrhenae rhizoma and hypoglycemic agents containing said derivatives | |
| JPH0261481B2 (it) | ||
| JP3823030B2 (ja) | エリテマトーデス性腎炎の予防および／または治療剤 | |
| GB2079150A (en) | Antiviral substance from Basidiomycetes | |
| US20020115158A1 (en) | Novel microorganism isolated from chinese elm (Ulmus sp.) and process for preparing exopolysaccharides by employing the microorganism | |
| KR20010040752A (ko) | 에이즈 치료제 | |
| KR840001510B1 (ko) | 삼지구엽초 sp속 식물로부터의 추출물 제조방법 | |
| JP3412159B2 (ja) | 食細胞活性化剤 | |
| KR20000061656A (ko) | 암치료용 한방 조성물 | |
| CN110721193B (zh) | 锁阳总多糖在制备治疗哮喘药物中的应用 | |
| JPH07238030A (ja) | 血糖降下剤 | |
| JPH07238031A (ja) | 血糖上昇抑制剤 |